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Following a single blind, cross-over and non-randomized design we investigated the effect of 7-day 
use of chlorhexidine (CHX) mouthwash on the salivary microbiome as well as several saliva and plasma 
biomarkers in 36 healthy individuals. They rinsed their mouth (for 1 min) twice a day for seven days 
with a placebo mouthwash and then repeated this protocol with CHX mouthwash for a further seven 
days. Saliva and blood samples were taken at the end of each treatment to analyse the abundance and 
diversity of oral bacteria, and pH, lactate, glucose, nitrate and nitrite concentrations. CHX significantly 
increased the abundance of Firmicutes and Proteobacteria, and reduced the content of Bacteroidetes, 
TM7, SR1 and Fusobacteria. This shift was associated with a significant decrease in saliva pH and 
buffering capacity, accompanied by an increase in saliva lactate and glucose levels. Lower saliva and 
plasma nitrite concentrations were found after using CHX, followed by a trend of increased systolic 
blood pressure. Overall, this study demonstrates that mouthwash containing CHX is associated with a 
major shift in the salivary microbiome, leading to more acidic conditions and lower nitrite availability in 
healthy individuals.
Chlorhexidine (CHX) has been commonly used in dental practice as antiseptic agent since 1970, due to its 
long-lasting antibacterial activity with a broad-spectrum of action1. Since then, many clinical trials have shown 
effective results of CHX for the clinical management of dental plaque and gingival inflammation and bleeding2–4. 
This is supported by other studies using in vitro methods and reporting positive results of CHX in reducing 
the proliferation of bacterial species associated with periodontal disease, such as Enterobacteria, Porphyromonas 
gingivalis, Fusobacterium nucleatum, as well as different species of Actinomyces and Streptococcus, including 
Streptococcus mutans, which is considered the main etiological agent of dental caries4,5. Other studies have 
also reported that the use of CHX was effective in the treatment of halitosis, especially in reducing the levels of 
halitosis-related bacteria colonising the dorsal surface of the tongue6.
The anti-microbial activity of CHX however, has been extensively studied using in vitro culture methods, 
which limit the identification and cultivation of all microorganisms in the environment4. To the best of our 
knowledge, only one recent study has investigated the effect of CHX mouthwash on mixed bacterial communi-
ties (microbiome) of the tongue using new genome sequencing techniques such as 16 S rRNA7. The study found 
differences in over 10 different species colonizing the tongue, and a lower microbial diversity after using CHX for 
a week, but did not analyse other parameters related to oral health such as pH, lactate production or buffering 
capacity7. Additionally, we and others have recently shown that the use of CHX in healthy subjects can attenuate 
the nitrate-reducing activity of oral bacteria by at least 80%8–11. This in turn leads to lower nitrite availability and 
an increase of blood pressure, suggesting that the oral microbiome can regulate cardiovascular health in healthy 
individuals and hypertensive patients8,11.
CHX is widely available over the counter and is used in healthy patients, but it is unknown whether it pro-
motes a healthy oral microbiome, or it may cause a shift to a microbiome associated with disease. Thus, the main 
aim of this study was to investigate the effects of 7-day use of CHX mouthwash on the oral microbiome of healthy 
participants, and its impact on several saliva markers such as pH, buffering capacity, lactate and glucose levels. We 
also investigated saliva and plasma concentrations of nitrate and nitrite with respect to blood pressure changes.
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Results
Thirty six healthy participants successfully completed this study (Table 1).
Oral microbiome analysis. Changes in the abundance of phyla are shown in Fig. 1A,B. The ratio between 
the main two phyla (Firmicutes/Bacteroidetes) is shown in Fig. 1C. CHX increased the abundance of Firmicutes 
(FDR < 0.001) and Proteobacteria (FDR < 0.001) and lowered the abundance of Bacteroidetes (FDR < 0.001), 
TM7 (FDR < 0.001), SR1 (FDR < 0.001) and Fusobacteria (FDR = 0.043).
Changes at genus level are presented in Fig. 1D,E. Within the phylum Firmicutes, the genus Bulleidia 
(FDR = 0.023) and Streptococcus (FDR = 0.020) were increased after using CHX, while 4 other genera decreased: 
Clostridium (FDR = 0.035), Megasphera (FDR = 0.001), Catonella (FDR < 0.001) and Lachnoanaerobaculum 
(FDR < 0.001). Regarding Proteobacteria, CHX led to an increase in Neisseria (FDR = 0.004), Hylemonella 
(FDR = 0.004) and Eikenella (FDR < 0.001) as well as a reduction in Campylobacter (FDR = 0.035). Changes 
in Bactoroidetes were led by an increase of Capnocytophaga (FDR < 0.001) and a decrease in Prevotella 
(FDR < 0.001). A significant reduction in non-assigned genera was found after CHX treatment (FDR = 0.004).
Figures 1F,G show the main changes at family level. Three families within the phylum Firmicutes increased 
after using CHX: Erysipelotrichaceae (FDR = 0.019), Streptococcaceae (FDR = 0.012) and Carnobacteriaceae 
(FDR = 0.012), whilst three other families decreased: Clostridiaceae (FDR = 0.027), Mogibacteriaceae 
(FDR < 0.001) and Lachnospiraceae (FDR = 0.005). The increase of the phylum Proteobacteria after CHX 
treatment was attributable to an increase in the abundance of 3 families: Neisseriaceae (FDR = 0.003), 
Comamonadaceae (FDR = 0.004) and Enterobacteriaceae (FDR = 0.005). This was also accompanied by a 
decrease of the family Campylobacteraceae (FDR = 0.027). On the other hand, lower abundance of the phy-
lum Bacteroidetes was attributable to lower abundance of 2 families: Prevotellaceae (FDR < 0.001) and 
Paraprevotellaceae (FDR < 0.001) and an increase of the family Flavobacteriaceae (FDR < 0.001). Within the phy-
lum Fusobacteria, the family Fusobacteriaceae (FDR = 0.003) showed the greatest reduction following CHX treat-
ment, whilst in the phylum TM7, F16 (FDR = 0.004) levels showed the greatest reduction. Finally, although the 
abundance of Actinobacteria did not significantly change after using CHX compared to placebo at phylum level, 
some families such as Actinomycetaceae (FDR = 0.007) and Corynebacteriaceae (FDR = 0.001) belonging to this 
phyla were significantly reduced by CHX. Finally, regarding alpha diversity, a significant decrease in the Shannon 
index was found after using CHX compared to placebo (FDR = 0.001) (Fig. 2A). Beta diversity was also signifi-
cantly affected by CHX as shown by greater dissimilarity of the Bray-Curtis plot compared to placebo (Fig. 2B).
Saliva and plasma markers. Salivary pH and buffering capacity were significantly reduced after using 
CHX compared to placebo (Fig. 3A,B). This was accompanied by a significant increase of salivary lactate and glu-
cose (Fig. 3C,D). CHX also led to lower oral nitrate-reducing capacity (Fig. 3E), which in turn, led to lower saliva 
and plasma nitrite availability (Fig. 3F,H) and increased salivary nitrate concentration (Fig. 3G).
Correlations. We found several moderate correlations between the abundance of oral bacteria and salivary 
biomarkers after using the placebo and CHX mouthwash (Fig. 4). In the placebo condition, greater abundance of 
Proteobacteria was negatively correlated with greater ability to form nitrite in the mouth (oral nitrate-reducing 
capacity) (Fig. 4A). Furthermore, greater abundance of Proteobacteria was associated with lower diastolic blood 
pressure (Fig. 4D). Plasma nitrite was negatively correlated with Bacteroidetes (Fig. 4B) and positively corre-
lated with Actinobacteria (Fig. 4E). Greater abundance of SR1 was also correlated with higher pH salivary values 
(Fig. 4C).
All these correlations changed after using CHX. We only found a positive correlation between Fusobacteria 
and saliva glucose (Fig. 4F), and a negative correlation between Actinobacteria and Proteobacteria and lactate and 
nitrite in saliva (Fig. 4G,H), respectively.
Blood pressure. When CHX was administered systolic blood pressure increased although it was not statis-
tically significant (Fig. 5A).
Discussion
This study showed that CHX mouthwash significantly changed the oral microbiome towards greater abundance of 
Firmicutes and Proteobacteria species, with lower abundance of Bacteroidetes, TM7, SR1 and Fusobacteria. These 
changes were associated with an increase in oral acidic conditions, represented by lower salivary pH. Saliva lactate 
and glucose concentrations were also elevated after using CHX. Additionally, CHX disrupted the ability of oral 
bacteria to reduce nitrate into nitrite, which may support our finding of lower circulatory nitrite bioavailability.
Age (years) 26 ± 1
Gender (F:M) 25:11
Weight (kg) 65.4 ± 2.0
Height (cm) 170.6 ± 1.9
Systolic blood pressure 103.6 ± 1.2
Diastolic blood pressure 62.8 ± 1.1
Mean arterial blood pressure 76.4 ± 1.0
Table 1. Main characteristic of participants (mean ± SEM).
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To the best of our knowledge, this is the first study showing the impact of 7-day use of CHX on the oral micro-
biome. A large body of literature suggests that mouthwashes with CHX are effective in reducing dental plaque 
accumulation, gingival inflammation and bleeding2–4. However, the view about oral bacteria and oral health has 
changed substantially over the last few years12. Current approaches, using genome sequencing to identify and 
quantify the microorganisms in dental biofilms, have revealed a much more complex ecosystem than previously 
appreciated13. Results from this study showed that CHX led to an increase in the abundance of some genera such 
as Neisseria, Streptococcus and Granulicatella, and lowered the abundance of Actinomyces, but did not affect the 
Figure 1. Absolute abundance and Linear Discriminant Analysis (LDA) scores in the main bacterial phyla 
(A,B), genus (D,E) and family (F,G) after a 7-day treatment with placebo and chlorhexidine (CHX). Figure C 
shows the ratio between the two main phyla (Firmicutes:Bacteroidetes) following each treatment. Operational 
Taxonomic Units (OTUs) with an asterisk were statistically significant (False Discovery Rate > 0.05).
Figure 2. Shannon’s index representing alpha-diversity (A) and Bray-Curtis index representing beta-diversity 
(B) (each dot represents an individual sample and ellipsis represents the 95% confidence regions for group) after 
a 7-day treatment with placebo and chlorhexidine (CHX).
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abundance of Veillonella. However, it remains difficult to determine whether these microbial changes suggest a 
shift towards a healthy oral environment, or whether they may increase the risk of oral disease, as both increases 
and decreases in the bacteria associated with caries and periodontal disease have been reported14. Consequently, 
additional studies are required to investigate bacterial communities during different disease states, with and with-
out CHX. Nevertheless, in the current study, we were able to associate genome sequencing measurements with 
other general markers of oral health, which allowed us to analyse more in detail the impact of mouthwash con-
taining CHX on oral and systemic health.
Lower microbial diversity as represented by the Shannon’s index was found after using CHX. This result is in 
agreement with another recent study showing lower diversity of bacteria colonizing the tongue7. These findings 
are relevant from a dental viewpoint since lower diversity of oral bacteria has been related to greater risk of oral 
diseases13. This may reflect the ecological pressure of lowered environmental pH. Healthy biofilms are associated 
with an active balance between slow rates of acid production and compensatory alkali generation, resulting in 
Figure 3. Saliva pH (A), saliva buffering capacity (B) and concentration of salivary lactate (C), glucose (D), 
nitrite (F), nitrate (G), as well as the oral nitrate-reducing capacity of bacteria (ONRC) (E) and concentration of 
plasma nitrite (H) and nitrate (I) after a 7-day treatment with placebo and chlorhexidine (CHX).
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an environment with a broadly neutral pH12. Surprisingly, the effect of CHX in salivary pH has only been inves-
tigated acutely in both in vivo15 and in vitro conditions16, but, no previous study analysed the impact of this anti-
bacterial compound over a period of days in healthy individuals. Our results showing lower saliva pH after using 
CHX are relevant, since decreased pH in saliva is associated with demineralization of tooth enamel and risk of 
caries, tooth loss and other dental problems17. Oral pH may differ between different oral conditions: whilst saliva 
pH is more alkaline in chronic gingivitis, it tends to be more acidic in chronic periodontitis18. Thus, in terms of 
salivary pH, CHX could therefore be more useful for managing gingivitis than periodontitis.
Saliva’s composition is another factor to pay attention when analysing the antimicrobial effectiveness of CHX. 
Several in vitro studies have indicated that saliva has a neutralizing effect on CHX19–21. Since CHX is a strongly 
cationic molecule it can react with anionic chemicals, resulting in inactivation of antimicrobial activity. We did 
not analyse the antimicrobial interaction between saliva and CHX in this study, but, we investigated the effect of 
CHX in several saliva markers. We found that CHX increased saliva lactate concentration and reduced its buff-
ering capacity. These changes are commonly associated with greater risk of oral disease22. Regarding bacteria, we 
found a negative correlation between the phylum Actinobacteria and saliva lactate concentration. This phylum 
comprises a large variety of Gram-positive bacteria and is known for its high production of bioactive compounds, 
including those with antimicrobial activity such as lantibiotics23. For instance, Nisin is one of the best known anti-
biotics for its highly effective bactericidal activity against most lactic acid bacteria24. Another important bacterial 
change associated with CHX administration was an increase of the major phyla Firmicutes, mainly comprised 
of an increase of the genus Streptococcus. This genus contains several families of lactic acid bacteria that are able 
to produce large quantities of this compound in the mouth25. On the other hand, we also found a significant 
Figure 4. Moderate degree and significant Pearson correlations (r > 0.40; P < 0.05) found between abundance 
of oral bacteria (Operational Taxonomic Units [OTUs] %) at phylum level and salivary markers after the 
placebo and chlorhexidine treatment. In the placebo condition, abundance of Proteobacteria was negatively 
correlated to the oral nitrate-reducing capacity of bacteria (ONRC) (A), and with lower levels of diastolic blood 
pressure (D). Abundance of Bacteroidetes was negatively associated with plasma nitrite (B), while abundance 
of Actinobacteria was positively correlated (E). Abundance of the phylum SR1 was positively associated with 
greater salivary pH. Following 7-day use of chlorhexidine, the abundance of Fusobacteria was correlated with 
greater concentration of glucose in saliva (F). Abundance of Actinobacteria was negatively correlated with saliva 
lactate (G), and abundance of Proteobacteria was also negatively correlated with saliva nitrite concentration (H).
Figure 5. Changes in systolic (SBP) and diastolic (DBP) blood pressure after 7-day use of placebo and 
chlorhexidine (CHX).
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decrease in the abundance of Bacteroidetes after using CHX. This was the second most abundant phyla in the oral 
cavity and some genera from this phyla such as Veillonella has been shown to be important in maintaining the 
acid/base conditions in the mouth26. Overall, these findings indicate that CHX promotes acidification of saliva by 
changing the ratio abundance of different families of bacteria that are essential to maintain the acid/base condi-
tions in the mouth of healthy people.
Oral nitrite synthesis is another factor to take into account, with regards to the acid/base conditions of the 
oral cavity27. Nitrite is a nitrogen compound that forms naturally in the mouth by the action of oral bacteria 
that can use exogenous (diet) or endogenous (nitric oxide synthesis) nitrate sources28. Species within the genus 
Veillonella and Actinomyces have been suggested to lead this reaction in the oral cavity29. Importantly, CHX had 
a detrimental effect lowering the abundance of bacteria from these groups and reducing nitrite availability. Thus, 
the detrimental effect of CHX on oral nitrite synthesis is another key point requiring further attention by dental 
professionals, since nitrite has been shown to have an inhibitory effect in the growth of periodontal bacteria 
which can also help to reduce the acid production from these strains27,30.
On the other hand, nitrite synthesis in the mouth has been shown to play a key role in cardiovascular control 
by enhancing circulatory nitrite availability. The vasodilatory effects of nitrite are well described by previous 
studies using intra-arterial infusions or dietary supplements with this anion31,32. Some recent studies, but not 
all9,33, have also found that the use of CHX mouthwash from 3 to 7 days led to higher blood pressure in healthy8 
and hypertensive individuals34. Participants from these studies had higher values of blood pressure compared to 
participants in our current study. In agreement with our results, Sundqvist et al.33 did not show a raise in blood 
pressure in a young and healthy group of females after using CHX for three days. Additional studies are required 
to improve our understanding about the hypertensive effect of CHX in males and females with different resting 
blood pressure levels and physiological status, especially, after new evidence has shown that CHX raised the 
mortality rate in hospitalized patients35. Overall, current studies seem to indicate that the use of CHX mouthwash 
leads to an increase of blood pressure, and this may be more accentuated in people with high blood pressure 
levels8,9,11,33.
This study has some limitations. For instance, it would be interesting to analyse the effect of CHX in patients 
with different oral health conditions such as gingivitis or periodontitis. We assessed the oral health status of par-
ticipants using a medical questionnaire, but it would be useful to undertake a full oral and dental examination, 
to analyse more in detail the concurrent effect of CHX on markers of periodontal health. Treatments were not 
randomized in this study due to the lack of available data indicating the time needed for the full recovery of the 
oral microbiome after one-week use of CHX. Consequently, there was not a wash out period between treatments. 
Furthermore, we analysed the microbiome in saliva as it provides an average of the oral microbiome, but bacterial 
communities can significantly differ among sites in distinct microbial niches in the oral cavity, therefore where 
the effects of CHX may also differ.
In conclusion this study indicates that a 7-day use of CHX mouthwash has a significant impact on the oral 
microbiome, as well as shift to an acidic environment, favourable for increased dental caries, and a reduction of 
the amount of oral nitrate-reducing bacteria, which contribute to cardiovascular health. Thus, these findings add 
to the growing body of evidence that the applications of CHX mouthwash should be more carefully considered, 
and that CHX could have detrimental effects on the healthy microbiome, and in turn cardiovascular health, 
requiring further investigation.
Methods
This study was approved by the Ethics Committee of the Faculty of Health & Human Sciences (University of 
Plymouth) and was carried out in accordance with the Code of Ethics of the World Medical Association 
(Declaration of Helsinki) for experiments involving human subjects. All the participants provided written con-
sent to participate in this study. This study was also registered on http://www.clinicaltrials.gov (NCT03871777; 
date of registration: 12/03/2019). Parts of the data presented herein were extracted from a study that examined 
the dietary consumption of nitrate in healthy vegetarian and omnivore subjects and the impact of inhibiting the 
nitrate-reducing activity of oral bacteria using CHX mouthwash in blood pressure9.
Main protocol. Following a single blinded, non-randomized, cross over design participants visited the lab-
oratory twice. Before the first trial, each participant received 14 tubes containing 10 mL placebo mouthwash 
(ultrapure unflavoured water), with which they rinsed their mouth for 1 min, twice a day for 7 days taking 
the final tube the night before the trial. Individuals were excluded from this study if they were smokers, using 
mouthwash or tongue scrapes, suffering from gingivitis or periodontitis, or exhibited a medical condition (e.g 
hypertension, diabetes). For standardisation, they were also given the same toothpaste to use throughout the 
duration of the study. Participants visited the laboratory on the eighth day between 8 and 10 am, having fasted 
overnight. Additionally, at least 24 h prior to their visit, they were sent written instructions via email to avoid 
drinks containing caffeine, such as tea or coffee, before the test and to refrain from strenuous exercise. Basic 
anthropometrical (weight and height) and physiological (blood pressure) parameters were measured before the 
collection of a plasma sample and a non-stimulated salivary sample (3 mL) as previously indicated9. Then, the oral 
nitrate-reducing capacity was also measured. At the end of the visit, the participant was given a further one-week 
supply of antibacterial mouthwash containing 0.2% CHX (Corsodyl Mint, GlaxoSmithKline, UK), instructed to 
use it as per the previous mouthwash (1 min, twice a day) and requested to return to the laboratory in 7 days to 
repeat all measurements in the same order.
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Bacterial analysis. Saliva pellets were extracted and frozen at −80 °C in a single sterile tube prior to 
metagenomic sequencing of the oral microbiome. DNA extraction of saliva and sequencing was performed as 
previously described at the Systems Biology Centre in Plymouth University (UK)9.
Saliva lactate, glucose and pH. Saliva concentrations of lactate and glucose were measured using a 
biochemistry analyser (YSI 2300 Stat Plus, YSI Life Sciences, USA). Salivary pH was measured using a single 
electrode digital pH meter (Lutron Electronic Enterprise Co Ltd., Model PH-208, Taiwan) that was calibrated 
following the manufacturer’s instructions.
Saliva buffering capacity. 250 µL of saliva was mixed with 750 µL of HCl (0.0033 m/L) and shaken for 
20 min. Then, salivary pH was measured using a single electrode digital pH meter (Lutron Electronic Enterprise 
Co Ltd., Model PH-208, Taiwan).
Saliva and plasma concentration of nitrate and nitrite. Whole blood was collected into 
lithium-heparin tubes (BD Vacutainer®, Becton Dickinson, Plymouth, UK) and rapidly centrifuged (4,000 rpm, 
4 °C, 10 min). The plasma was then separated, and frozen at −80 °C until further analyses of nitrate and nitrite. 
Both anions were measured in saliva and plasma using ozone-based chemiluminescence as previously described36.
Oral-nitrate reducing capacity. Participants were instructed to hold 10 mL of water containing sodium 
nitrate (80 μmol) in their mouth for 5 min. The mouth rinse was collected into a sterile Falcon tube and centri-
fuged (4,000 rpm, 4 °C) for 10 min. The supernatant was collected and stored at −80 °C before measurement of 
absolute nitrite concentration as indicated above.
Blood pressure measurement. Participants rested in a supine position for 30 min, before three successive 
readings were taken (four if variation in systolic or diastolic blood pressure of >4 mmHg was found), using an 
oscillometric device (Connex ProBP 3400 Digital Blood Pressure Device, Welch Allyn UK Ltd.) with 1 min rest 
between readings. The second and third readings were averaged to determine mean clinical blood pressure.
Statistical analyses. General data are presented as mean (95% confidence interval). Normal distribution of 
the sample was assessed using Shapiro-Wilk test. Differences between treatments (placebo vs CHX) were analysed 
using paired t-tests (data normally distributed) or Wilcoxon test (data non-normally distributed). Operational 
Taxonomic Units (OTUs) assigned to the major salivary bacterial phyla, and genera were analysed using the 
linear discriminant analysis (LDA) effect size (LEfSe) method37. The False Discovery Rate (FDR) was used at an 
alpha of 0.05 as previously indicated38. The Pearson correlation test was used to investigate relationship between 
relative oral bacterial abundance (OTUs %) and salivary markers. Bioinformatics analysis was performed using 
the OTUs_biom table generated in with MicrobiomeAnalysit39.
Data availability
The datasets generated during and/or analysed during the current study are available from the corresponding 
author on reasonable request. All data generated or analysed during this study are included in this published 
article.
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